Equities Analysts Issue Forecasts for Allogene Therapeutics, Inc.’s Q1 2026 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at Zacks Research raised their Q1 2026 earnings per share estimates for Allogene Therapeutics in a research report issued on Wednesday, September 18th. Zacks Research analyst R. Department now anticipates that the company will earn ($0.43) per share for the quarter, up from their prior forecast of ($0.45). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.38) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.80) EPS.

A number of other research firms also recently commented on ALLO. Oppenheimer assumed coverage on shares of Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 target price for the company. Canaccord Genuity Group cut their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Allogene Therapeutics in a report on Thursday, August 15th. Piper Sandler initiated coverage on Allogene Therapeutics in a research note on Friday, May 31st. They set an “overweight” rating and a $11.00 price target for the company. Finally, Truist Financial reiterated a “buy” rating and issued a $14.00 price objective (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $9.96.

Allogene Therapeutics Price Performance

ALLO opened at $2.67 on Monday. The stock has a market capitalization of $558.03 million, a price-to-earnings ratio of -1.49 and a beta of 0.83. The firm has a 50 day moving average price of $2.69 and a 200-day moving average price of $2.97. Allogene Therapeutics has a twelve month low of $2.01 and a twelve month high of $5.78.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%.

Hedge Funds Weigh In On Allogene Therapeutics

A number of hedge funds have recently made changes to their positions in ALLO. Primecap Management Co. CA boosted its stake in Allogene Therapeutics by 4.1% in the 2nd quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock worth $13,212,000 after purchasing an additional 221,840 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after acquiring an additional 1,806,147 shares in the last quarter. Perceptive Advisors LLC purchased a new position in Allogene Therapeutics during the second quarter valued at $6,349,000. Dimensional Fund Advisors LP increased its holdings in Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after acquiring an additional 507,021 shares during the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in Allogene Therapeutics in the 2nd quarter worth $5,192,000. Institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).